Frontiers in Cellular and Infection Microbiology (Mar 2023)
Efficient isolation of rare B cells using next-generation antigen barcoding
- Jonathan Hurtado,
- Jonathan Hurtado,
- Jonathan Hurtado,
- Claudia Flynn,
- Claudia Flynn,
- Claudia Flynn,
- Jeong Hyun Lee,
- Jeong Hyun Lee,
- Jeong Hyun Lee,
- Eugenia C. Salcedo,
- Eugenia C. Salcedo,
- Eugenia C. Salcedo,
- Christopher A. Cottrell,
- Christopher A. Cottrell,
- Christopher A. Cottrell,
- Christopher A. Cottrell,
- Patrick D. Skog,
- Dennis R. Burton,
- Dennis R. Burton,
- Dennis R. Burton,
- Dennis R. Burton,
- David Nemazee,
- William R. Schief,
- William R. Schief,
- William R. Schief,
- William R. Schief,
- William R. Schief,
- Elise Landais,
- Elise Landais,
- Elise Landais,
- Devin Sok,
- Devin Sok,
- Devin Sok,
- Bryan Briney,
- Bryan Briney,
- Bryan Briney,
- Bryan Briney
Affiliations
- Jonathan Hurtado
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States
- Jonathan Hurtado
- Center for Viral Systems Biology, Scripps Research, La Jolla, CA, United States
- Jonathan Hurtado
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- Claudia Flynn
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States
- Claudia Flynn
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- Claudia Flynn
- IAVI Neutralizing Antibody Center, Scripps Research, La Jolla, CA, United States
- Jeong Hyun Lee
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- Jeong Hyun Lee
- IAVI Neutralizing Antibody Center, Scripps Research, La Jolla, CA, United States
- Jeong Hyun Lee
- International AIDS Vaccine Initiative, New York, NY, United States
- Eugenia C. Salcedo
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- Eugenia C. Salcedo
- IAVI Neutralizing Antibody Center, Scripps Research, La Jolla, CA, United States
- Eugenia C. Salcedo
- International AIDS Vaccine Initiative, New York, NY, United States
- Christopher A. Cottrell
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States
- Christopher A. Cottrell
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- Christopher A. Cottrell
- IAVI Neutralizing Antibody Center, Scripps Research, La Jolla, CA, United States
- Christopher A. Cottrell
- International AIDS Vaccine Initiative, New York, NY, United States
- Patrick D. Skog
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States
- Dennis R. Burton
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States
- Dennis R. Burton
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- Dennis R. Burton
- IAVI Neutralizing Antibody Center, Scripps Research, La Jolla, CA, United States
- Dennis R. Burton
- Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States
- David Nemazee
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States
- William R. Schief
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States
- William R. Schief
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- William R. Schief
- IAVI Neutralizing Antibody Center, Scripps Research, La Jolla, CA, United States
- William R. Schief
- International AIDS Vaccine Initiative, New York, NY, United States
- William R. Schief
- Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States
- Elise Landais
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- Elise Landais
- IAVI Neutralizing Antibody Center, Scripps Research, La Jolla, CA, United States
- Elise Landais
- International AIDS Vaccine Initiative, New York, NY, United States
- Devin Sok
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- Devin Sok
- IAVI Neutralizing Antibody Center, Scripps Research, La Jolla, CA, United States
- Devin Sok
- International AIDS Vaccine Initiative, New York, NY, United States
- Bryan Briney
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States
- Bryan Briney
- Center for Viral Systems Biology, Scripps Research, La Jolla, CA, United States
- Bryan Briney
- Consortium for HIV/AIDS Vaccine Development, Scripps Research, La Jolla, CA, United States
- Bryan Briney
- San Diego Center for AIDS Research, Scripps Research, La Jolla, CA, United States
- DOI
- https://doi.org/10.3389/fcimb.2022.962945
- Journal volume & issue
-
Vol. 12
Abstract
The ability to efficiently isolate antigen-specific B cells in high throughput will greatly accelerate the discovery of therapeutic monoclonal antibodies (mAbs) and catalyze rational vaccine development. Traditional mAb discovery is a costly and labor-intensive process, although recent advances in single-cell genomics using emulsion microfluidics allow simultaneous processing of thousands of individual cells. Here we present a streamlined method for isolation and analysis of large numbers of antigen-specific B cells, including next generation antigen barcoding and an integrated computational framework for B cell multi-omics. We demonstrate the power of this approach by recovering thousands of antigen-specific mAbs, including the efficient isolation of extremely rare precursors of VRC01-class and IOMA-class broadly neutralizing HIV mAbs.
Keywords
